In recent years, monoclonal antibodies achieved remarkable success in cancer treatment. As an experienced CRO, Creative Biolabs owns extensive knowledge and deep understanding of protein discovery, engineering, manufacturing, etc. Also, we are experienced in cancer serology, mechanism of action, the interaction between the immune system, and research in oncology. Our scientists have initiated various Next-IO™ programs aiming a wide range of targets. All available for your flexible choice. This anti-CTLA-4 × CD40 combination antibody program aims to develop combination therapy that could recognize and potentially, against CTLA4 and CD40.
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, CD152), an immune checkpoint, is a membrane glycoprotein involving in the suppression of T cell immune functions like proliferation and cytokine production. CTLA-4 is a negative regulator of anti-tumor T cell upon recognition of their ligands. Anti-CTLA-4 antibodies are developed to inhibit the CTLA-4 activities and reverse the anti-tumor activities of T cell. Therapeutic antibodies targeting CTLA-, ipilimumab, and tremelimumab, are approved to be efficient in a wide range of hematological malignancies and solid tumors.
CD40 is a member of the tumor necrosis factor receptor superfamily. Activation of CD40 might able to reverse T cell-dependent anti-tumor immune reaction. CD40 agonists offer novel therapeutic approaches to anticancer immunity by activating DC, myeloid cells, and B cells (see Fig.2). CD40 mAb can increase these cells’ ability to present TAAs to functional cytotoxic T lymphocytes (CTLs). There already have some data supporting agonist CD40 monoclonal antibody that can reverse tumor-induced immune suppression and facilitate the T cell-dependent anti-tumor immunity in pancreatic ductal adenocarcinoma (PDA).
From what we know, T cells are prime modulators in tumor immune surveillance and tumor-infiltrating T-cells play the major effector in antitumor immunity. With the knowledge of the therapeutic functions of CD40 mAb and CTLA-4 mAb, our scientists propose this combination therapy program targeting CD40 and CTLA-4 simultaneously. We will carefully choose indicators after thorough research. From discovery to development, every step will be accompanied by our guarantees. With our rich experience in end-to-end antibody discovery and development, we have the confidence to advance the project efficiently.
For other questions about this combination therapy program, please feel free to reach out to our scientists for assistance.
So far, not one combination therapy targeting CD40 and CTLA-4 is approved. Studies on this combination approach are still in the early discovery stage. We believe our program of discovering and researching anti-CD40 and CTLA-4 therapy is at the cutting edge of the field and have certain marking and sale potential.
Creative Biolabs is dedicated to providing Next-IO™ programs to the market and committed to delivering the finalized program to our partners within about 1.5 years. The accurate timeline will be determined on a case-by-case basis. Here is a draft timeline for your glance.
Fig.1 The timeline of Next-IOᵀᴹ programs.
Creative Biolabs is excited to offer years of valuable CRO experience to our partners and achieve more strategic. We are committed to maximizing the result of our programs in a timely manager. No matter you have an idea or not at this moment, our scientists will tailor the program per the needs of you and your team. As a leading CRO company, we believe our collaboration will unleash the creative spirit and help you achieve greater success in immuno-oncology.
If you are interested in our programs, please feel free to contact us for more details.
For Research Use Only | Not For Clinical Use
Download our brochure